^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Promega

    i
    Other names: Promega | Promega Corporation
    Related tests:
    Evidence

    News

    3ms
    Promega and Watchmaker Genomics Announce Strategic Partnership to Advance Molecular Analysis with Next-Generation Reverse Transcriptase (Promega Press Release)
    "Promega has entered a strategic partnership with Watchmaker Genomics to license a novel engineered reverse transcriptase. Designed for enhanced accuracy and sensitivity in RNA analysis, the enzyme will enhance Promega capabilities to manufacture and deliver both catalog and customized solutions for clinical, applied, and pharmaceutical molecular applications."
    Clinical data
    1year
    Promega unveils GloMax® Galaxy Bioluminescence Imager for illuminating protein dynamics in real time (Promega Press Release)
    "Promega Corporation...today unveils the new GloMax® Galaxy Bioluminescence Imager being showcased at the annual Society for Neuroscience (SFN) 2024 conference in Chicago October 5-9."
    Clinical data
    2years
    Promega to Develop Microsatellite Instability (MSI) Companion Diagnostic IVD Kit in Collaboration With GSK (Businesswire)
    "Promega Corporation today announced it plans to develop and commercialize a microsatellite instability (MSI) companion diagnostic (CDx) IVD kit with GSK to identify adult cancer patients with MSI-H solid tumors who may be eligible for potential treatment with GSK’s Jemperli (dostarlimab-gxly). The collaboration agreement leverages the companies’ complementary strengths to expand personalized healthcare options to more patients using high quality diagnostic tools and treatments....The development of this CDx IVD kit is part of GSK’s post marketing commitment to the FDA to make a companion diagnostic available to support the safe and effective use of Jemperli in patients with MSI-H solid tumors."
    Licensing / partnership
    |
    Jemperli (dostarlimab-gxly)
    over3years
    Stilla and Promega announce co-marketing agreement to offer complete digital PCR workflow solution (Stilla Technologies Press Release)
    "Stilla Technologies, the multiplex digital PCR company, and Promega Corporation today announced a co-marketing agreement that combines sample preparation with the latest Maxwell® systems and digital PCR on the six-color naica® system. With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery."
    Licensing / partnership
    almost4years
    New study validates novel markers for detecting microsatellite instability in multiple cancers (BioSpace)
    "Researchers from Johns Hopkins University have shown that a new panel of long mononucleotide repeats (LMR) might offer advantages over traditional microsatellite instability (MSI) detection methods in certain types of solid tumors. The study, published in the February issue of Journal of Molecular Diagnostics, is the first to use the PCR-based Promega Corporation LMR MSI Analysis System to detect MSI in endometrial, prostate and other cancers."
    Clinical data